RE:Average cost to bring drug candidate to market = US$2.3 Bln More pump Noteable... "prime" the innate/adaptive immune system, which pelareorep has shown it can address."
Yes, and Pfizer knows this also, what they do not know, and which YOU do not know either, is whether the addition of a Checkpoint inhibitor to the doublet of Pela + Pax, gives significantly more durable response, than with Pela and Pax without a CPI.
The primary endpoints are already measured, PFS. But clearly those aren't showing anything significant of Pfizer would have made a move already.
Given that you think ONCY is worth 8 billion or so, why do you think that HC Wainwright only reckons on the stock being worth $15... strange that or the last two or three years of your pumping that the stock price has gone nowhere..
Now we hear in Matt's recent 'chat' that we will need 4-500 patients in a phase III... But before he embarked on this, FDA 'insisted' we understand how Pela works, we were sold the story that by developing biomarkers, we could lessen that number down to 250, and thus save time..
Save time..??? We have now waited 5 years to be back at exactly where we were in terms of a Phase III trial size... a stock valued at 75 million and chump change is not going to get bought for 8 or 9 billion... jeez.